SCHEMBL4635208

SCHEMBL4635208

CCCOc1cccc(C(=O)c2ccccc2)c1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.50
KDM4E B2RXH2 2/20 0.50
ALOX15 P16050 2/20 0.50
HSD17B10 Q99714 2/20 0.50
MAPK1 P28482 1/20 0.50
ABCB1 P08183 2/20 0.49
CNR1 P21554 1/20 0.49
CNR2 P34972 1/20 0.49
DRD2 P14416 1/20 0.49
DRD1 P21728 1/20 0.49
DRD3 P35462 1/20 0.49
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
HIF1A Q16665 1/20 0.47
CCNB2 O95067 1/20 0.46
CCNE2 O96020 1/20 0.46
CDK1 P06493 1/20 0.46
CCNB1 P14635 1/20 0.46
CCNE1 P24864 1/20 0.46
CDK2 P24941 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15104997 0.96 MAPT (0.47) MAPTKDM4EALOX15HSD17B10MAPK1
SCHEMBL3820072 0.90 LMNA (0.58) MAPTKDM4EALOX15HSD17B10MAPK1
SCHEMBL26097662 0.90 LMNA (0.58) MAPTKDM4EALOX15HSD17B10MAPK1
SCHEMBL2048120 0.90 LMNA (0.58) MAPTKDM4EALOX15HSD17B10MAPK1
SCHEMBL7386575 0.88 RAB9A (0.57) MAPTKDM4EALOX15HSD17B10MAPK1
SCHEMBL5598745 0.88 DRD2 (0.61) MAPTKDM4EABCB1CNR1CNR2
SCHEMBL30444952 0.88 DRD2 (0.61) MAPTKDM4EABCB1CNR1CNR2
Water SCHEMBL27563973 0.86 DRD2 (0.59) MAPTKDM4EABCB1CNR1CNR2
SCHEMBL28209598 0.85 CCNB2 (0.52) MAPTABCB1CNR1CNR2DRD2
SCHEMBL4963086 0.84 ALDH1A1 (0.51) KDM4EHSD17B10KMT2AMEN1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260000076-A1 ANTIMICROBIAL COMBINATIONS CLARIANT INT LTD (CH) 2026-01-01 US disclosed
EP-4637352-A2 ANTIMICROBIAL COMBINATIONS CLARIANT INTERNATIONAL LTD (CH) 2025-10-29 EP disclosed
EP-4598500-A1 COMBINATION COMPRISING A GLUCAMIDE AND A CO-EMULSIFIER CLARIANT INTERNATIONAL LTD (CH) 2025-08-13 EP disclosed
EP-4245293-B1 USE OF SUGAR AMINES AS COMPLEXING AGENTS CLARIANT INT LTD (CH) 2025-08-06 EP disclosed
EP-4557953-A1 ANTIMICROBIAL COMBINATIONS CLARIANT INTERNATIONAL LTD (CH) 2025-05-28 EP disclosed
CN-119997951-A Method for preventing, alleviating and/or treating PTGS 2-induced skin disorders and related dysfunctions 西姆莱斯股份公司 2025-05-13 CN disclosed
CN-119968452-A Perfume mixture (VI) 西姆莱斯股份公司 2025-05-09 CN disclosed
EP-3735827-B1 COMPOSITION FOR INHIBITING MICRO-ORGANISMS CLARIANT INT LTD (CH) 2025-04-09 EP disclosed
CN-119790128-A Perfume mixture (III) 西姆莱斯股份公司 2025-04-08 CN disclosed
EP-3554644-B1 WATER-SOLUBLE AND/OR WATER-SWELLABLE HYBRID POLYMER CLARIANT INT LTD (CH) 2025-03-19 EP disclosed
CN-112334125-B Cosmetic preparation 花王株式会社 2022-06-10 CN disclosed
EP-4008406-A1 COSMETIC COMPOSITION BASED ON ACROYL TAURATE TYPE POLYMERS Clariant International Ltd (CH) 2022-06-08 EP disclosed
US-11339241-B2 Water-soluble and/or water-swellable hybrid polymer CLARIANT INTERNATIONAL LTD. (CH) 2022-05-24 US disclosed
US-11306170-B2 Water-soluble and/or water-swellable hybrid polymer CLARIANT INTERNATIONAL LTD. (CH) 2022-04-19 US disclosed
CN-114340585-A Solid cosmetic 信越化学工业株式会社 2022-04-12 CN disclosed
CN-108623809-B Organic group-modified silicone resin, method for producing same, and cosmetic 信越化学工业株式会社 2022-03-15 CN disclosed
EP-1928400-A2 SKIN CARE COMPOSITION COMPRISING INTERFERENCE PIGMENTS The Procter and Gamble Company (US) 2008-06-11 EP disclosed
WO-2007031970-A2 SKIN CARE COMPOSITION COMPRISING INTERFERENCE PIGMENTS THE PROCTER & GAMBLE COMPANY (US) 2007-03-22 WO disclosed
EP-0478747-A1 SURFACE MODIFIED, U.V. STABILIZED, POLYVINYL CHLORIDE ARTICLE ATOCHEM NORTH AMERICA, INC. (US) 1992-04-08 EP disclosed
WO-1991016143-A1 SURFACE MODIFIED, U.V. STABILIZED, POLYVINYL CHLORIDE ARTICLE ATOCHEM NORTH AMERICA, INC. (US) 1991-10-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11339241-B2 Water-soluble and/or water-swellable hybrid polymer PWWP2B, CD44, ALG1 MAPT 217/4885KDM4E 4881/4885ALOX15 285/4885
US-20260000076-A1 ANTIMICROBIAL COMBINATIONS FFAR1, ELOVL3, ACAD11 MAPT 3408/4885KDM4E 3135/4885ALOX15 71/4885
US-11306170-B2 Water-soluble and/or water-swellable hybrid polymer ALG1, CD44, PWWP2B MAPT 461/4885KDM4E 4875/4885ALOX15 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.